HCV NS5A Mutation Detection via TaqMan Probes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting mutations in the hepatitis C virus (HCV) NS5A protein at position 93 are either non-quantitative or excessively costly, making it difficult to efficiently measure the presence or absence of mutations in clinical practice, especially when dealing with various HCV genotypes and variations.
Innovation Solution
A method involving the synthesis of cDNA from HCV RNA and real-time PCR using specific probes and primers designed to target the region encoding amino acid 93, allowing for quantitative measurement of mutations while minimizing the impact of HCV variations, using probes such as those with sequences set forth in SEQ ID NOs: 1, 2, and 18, and primers like those in SEQ ID NOs: 11 and 12.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If direct sequencing method is used to detect mutation in HCV NS5A protein at position 93, then cost is reduced, but quantitative measurement capability is lost
Solution Approach 1:
The patent introduces a TaqMan probe as an intermediary element that enables quantitative detection. The probe contains a fluorescent reporter and quencher, allowing real-time monitoring of PCR amplification. By designing probes specific to wild-type and mutated sequences, the system can simultaneously detect both forms and calculate mutation rates, thus achieving quantitative measurement without requiring expensive next-generation sequencing while maintaining cost-effectiveness through conventional PCR technology.
Solution Approach 2:
The patent changes the detection parameter from qualitative sequence identification to quantitative fluorescence signal measurement. By using fluorescent probes that emit signals proportional to the amount of target sequence present, the system transforms the detection into a quantitative measurement. The fluorescent signal intensity directly correlates with the copy number of wild-type or mutated sequences, enabling precise calculation of mutation rates at position 93 of the NS5A protein.
2Measurement precision
If next-generation sequencer is used to detect mutation in HCV NS5A protein at position 93, then quantitative measurement capability is achieved, but cost per run becomes excessively high
Solution Approach 1:
The patent employs disposable TaqMan probes that are significantly cheaper than next-generation sequencing runs. These probes are designed to be single-use, containing the necessary fluorescent reporters and quenchers in a conventional PCR reaction setup. The low cost of these probes, combined with the affordability of conventional PCR instrumentation, makes quantitative mutation detection accessible to routine clinical practice without requiring expensive sequencing facilities.
Solution Approach 2:
The patent replaces the complex mechanical and computational systems of next-generation sequencing with a simpler optical detection system. Instead of using sophisticated sequencers that require specialized infrastructure and bioinformatics analysis, the system uses fluorescent probes detected by standard PCR instruments. This substitution maintains quantitative measurement capability while dramatically reducing equipment requirements and operational costs.
3Device complexity
If conventional detection method is used for HCV mutation detection, then simplicity is maintained, but ability to handle various HCV genotypes and variations is insufficient
Solution Approach 1:
The patent designs a universal detection system that can accommodate multiple HCV genotypes and variations through a single platform. By creating a master probe set that includes probes for wild-type sequences and probes for common mutations across different genotypes, the system achieves multi-functionality. The same PCR reaction conditions and detection mechanism work for all genotypes, maintaining simplicity while expanding versatility to handle the diversity of HCV strains globally.
Solution Approach 2:
The patent segments the detection system into distinct probe components, each targeting specific sequences (wild-type or specific mutations). This segmentation allows the system to independently detect different genotypes and variations without interference. Each probe is designed to be genotype-specific or variation-specific, enabling the system to handle diverse HCV strains by simply adding the appropriate probes to the reaction mixture while maintaining the same overall simple PCR-based platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the rapid, cost-effective, and quantitative detection of mutations in the HCV NS5A protein at position 93, effectively addressing the limitations of existing methods by providing accurate measurement across various HCV genotypes and variations.
Implementation Method 1
synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample
Implementation Method 2
performing a real-time PCR with a cycling probe method using, as a template, the cDNA
Implementation Method 3
performing a real-time PCR with a cycling probe method
Data Source
AI summary
A method for detecting a mutation in an amino acid at position 93 of a hepatitis C virus NS5A protein, the method including:synthesizing cDNA using, as a template, hepatitis C virus RNA in a sample; andperforming a real-time PCR with a cycling probe method using, as a template, the cDNA;wherein a primer set used in the real-time PCR is a certain primer set; andwherein probes used in the real-time PCR include certain probes.